Purpose of review Neuromyelitis optica (NMO) is an antibody-mediated inflammatory disease of the central nervous system with a predilection for the optic nerves, spinal cord and certain brain regions. It has a distinct pathogenesis relating to aquaporin-4 autoimmunity and complement-mediated injury. This knowledge has translated into targeted efforts to develop novel, disease-specific treatments. In this review, we discuss evidence supporting the use of currently available treatments for acute exacerbations and for long-term disease modification. We also discuss the risks and benefits of available and emerging immunotherapies.
INTRODUCTION
Neuromyelitis optica (Devic's disease; NMO) is an inflammatory disease of the central nervous system (CNS). The disease, which was considered a variant of multiple sclerosis (MS) in the past, is now known to have distinct clinical, pathological and immunological features. The identification of NMO-IgG, a pathogenic antibody against aquaporin-4 (AQP4), delineated NMO from MS [1,2]. The definitive diagnosis of NMO requires the presence of optic neuritis and transverse myelitis. Limited forms of the disease associated with NMO-IgG seropositivity are termed NMO spectrum disorder (NMOSD). Early, accurate diagnosis of NMO or NMOSD has major implications for patient outcomes by refining the choice of optimal immunotherapies to mitigate the risk of relapses and disability. Several disease-modifying agents used in MS patients should be avoided in NMO because of their apparent lack of efficacy or, in some cases, their potential to exacerbate the disease.
CLINICAL AND DIAGNOSTIC FEATURES
Worldwide prevalence of NMO ranges from 0.5 to 4.4 cases per 100 000 [3 & ]. It is relatively rare in the USA and European countries, with a prevalence that is 50-100 times lower than that of MS [4,5 & ] . In people of Asian or African descent, however, the prevalence of NMO is only two to four times lower than the prevalence of MS, primarily because MS is less common in these populations [6 & ]. The disease is three to seven times more common in women than men [3 & , 8, 9] . The mortality directly associated with NMO attacks ranges from 7 to 30%, mostly attributed to neurogenic respiratory failure [10] [11] [12] . Older age at disease onset is strongly associated with poorer outcomes [10] . However, published mortality rates are mostly drawn from an era with more limited understanding of disease mechanisms and less successful immunosuppressive treatments.
Optic neuritis and transverse myelitis are the defining features of NMO and may either occur simultaneously or sequentially, separated by days to several years. In comparison to MS, involvement of the brain is less common; when affected, however, there is a predilection for the dorsal brainstem and hypothalamus. Neurologic manifestations of NMO, therefore, may include refractory hiccups, nausea and vomiting, and respiratory failure [13, 14] .
Limited forms of NMO, in which either optic neuritis or transverse myelitis has not occurred [15] , are seen in association with NMO-IgG seropositivity; this presentation is termed NMOSD [16] . Several clinical and diagnostic features may suggest NMOSD and prompt clinicians to test for NMO-IgG in order to establish the diagnosis. These features include optic neuritis with severe vision loss, poor visual recovery, simultaneous or rapidly sequential bilateral involvement of both eyes, chiasmal lesions and severe retinal nerve fibre layer loss demonstrated using optical coherence tomography (OCT) [17,18 & ,19] . Similarly, NMO-related transverse myelitis is often characterized by a contiguous lesion extending over three or more vertebral segments [longitudinally extensive transverse myelitis (LETM)]. It can lead to severe disability with limited recovery. As described above, brain lesions can occur, but typically not in a distribution that is characteristic of MS [20 && ]. NMOSD can coexist with autoimmune conditions such as systemic lupus erythematosus, Sjög-ren's syndrome, myasthenia gravis and others [16, 21, 22] . NMO-IgG testing should therefore be considered when optic neuritis or transverse myelitis occurs in patients in whom these diagnoses are established or suspected. Case reports of NMO coexisting with cancer suggest that occasionally the disease may be a paraneoplastic immune phenomenon [23 && ].
DISEASE AND IMMUNOPATHOGENESIS
The target antigen of NMO-IgG is AQP4, a cellmembrane water channel protein that is expressed predominantly at astrocytic end-feet forming the blood-brain barrier, as well as in subpial and subependymal regions [2] . Although AQP4 is also expressed in human tissues outside the CNS, NMO-IgG mediated disease outside the CNS is rare. Several factors contribute to NMO's predilection for particular regions of the CNS, including the absence of protective membrane complement regulators at astrocytic end-feet as well as the heterotetramers of AQP4 channels in the optic nerves and spinal cord [24, 25 && ]. Binding of NMO-IgG to AQP4 causes astrocytic injury through activation of the classical complement pathway and antibody-dependent cell-mediated cytotoxicity (ADCC). The binding downregulates AQP4 and the glutamate transporter EEAT2, thus disrupting cellular water and glutamate homeostasis [26] . Antibody and complement deposition attracts inflammatory cells, including T and B lymphocytes, macrophages, neutrophils and eosinophils [27] . Injury to oligodendrocytes and resulting demyelination are the downstream effects of these immune responses [27] .
Several assays exist to identify NMO-IgG in patients with suspected NMO, but the sensitivity of these tests varies greatly. Recombinant human AQP4-based assays are more sensitive than the original mouse tissue-based indirect immunofluorescence (IIF) NMO-IgG assay [28] . Among the recombinant human protein based assays, the sensitivity declines in the following order: quantitative fluorescenceactivated cell-sorting assay (FACS), transfected cellbased assay (CBA; available commercially), ELISA (available commercially) and immunoprecipitation assay (IPA) [28,29 && ]. When a patient with suspected
KEY POINTS
Early diagnosis and institution of disease-specific immunomodulating agents is crucial for prevention of attack-induced disability.
Results from randomized controlled treatment trials in NMO patients are not available at this time.
Acute exacerbations are managed with glucocorticoids and/or plasmapheresis.
On the basis of expert opinion, available safety and efficacy data, current first-line options for relapse prophylaxis include rituximab, mycophenolate mofetil and azathioprine.
Three ongoing clinical trials may provide more robust efficacy data for new drugs.
Various more selective and potentially safer therapeutic strategies are currently under clinical evaluation.
NMO has negative serology, it is often helpful to use a more sensitive method [8] .
Patients that are NMO-IgG seropositive have a higher likelihood of relapsing disease than patients who are seronegative [30, 31] . In established NMO patients, however, the quantified NMO-IgG titre typically does not correlate with disease activity [32] [33] [34] . At this time, therefore, there is no established clinical utility in repeated assessment of NMO-IgG serum titres in an individual patient. . This subset of patients seems to have a better prognosis than patients with NMO-IgG antibodies or those who are seronegative for both antibodies. The pathogenic mechanism of MOG antibody remains unclear; animal passive transfer experiments are hampered by differences in human and rodent MOG structure [39] .
SERONEGATIVE NMO AND MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODIES

CURRENT THERAPIES
Although no randomized treatment trials have been completed, available retrospective and open-label, uncontrolled data permit several tentative conclusions regarding the use of immunomodulating therapies for acute attacks and prevention of future relapses [40] . The mechanisms of action for available treatments are summarized in Table 1 .
Treatment of acute exacerbations
Treatment of acute exacerbations aims at minimizing residual disability and preventing mortality. Unlike in MS, full recovery following an attack in NMO is rare, especially if untreated [14] , and there may be continuous accrual of disability with every subsequent attack.
When a diagnosis of NMO is confirmed or suspected, any acute exacerbation should ideally be treated promptly with high-dose intravenous methylprednisolone for 3-5 days [41] . When recovery is incomplete or slow, a prednisone taper for several months may be considered [40] . Plasmapheresis or plasma exchange (PLEX) has been used for severe, progressive or refractory attacks either concomitantly or immediately following a course of glucocorticoids [42] . Its use is supported by beneficial effects shown in a randomized, controlled, doublemasked clinical trial in 22 patients with severe demyelinating disease, including two with definite NMO, four with acute transverse myelitis and one with recurrent myelitis [43] . Retrospective studies have also shown that PLEX in combination with glucocorticoids is superior to glucocorticoids alone with respect to final visual outcome in patients with NMO [44, 45] . PLEX depletes the pathogenic antibodies and probably also cytokines and complement components, although its mechanisms of action have not been fully elucidated [46 & ,47]. Complications occur in about 4% of patients and are either related to intravenous access (in 0.15%) or to the procedure itself, such as hypocalcemia stemming from citrate toxicity [48] . Currently, a multicentre study is being conducted to evaluate PLEX as a maintenance therapy to prevent attacks in patients who did not respond to other immunosuppressants.
Treatment with intravenous immunoglobulin (IVIg) was evaluated in a small retrospective study of 11 patients with NMO who failed to respond to glucocorticoids with or without PLEX [49 & ]. Five patients improved, suggesting that IVIg may have a role in treating acute exacerbations. Mild adverse effects are common, including headache, nausea and constitutional symptoms; serious adverse reactions, particularly thromboembolic events and acute renal failure, can be minimized by identifying patients' risk factors and making appropriate adjustments to the administration protocol [50] .
Prevention of relapses
Several immunosuppressive agents have been accepted as long-term disease-modifying treatment for patients with NMO, based upon expert opinion, retrospective studies and prospective open-label series [40] . These include rituximab (RTX), mycophenolate mofetil (MMF) and azathioprine (AZA). Other medications that have also been used to treat NMO patients include methotrexate (MTX), mitoxantrone and cyclophosphamide (CYC).
AZA was the first agent to show efficacy in preventing NMO relapses [51] . The medication is administered often in combination with prednisone typically at a dose range from 5 to 60 mg. Reported reductions in the absolute annualized relapse rate (ARR) range from 0.36 to 1.63 [52, 53 && -55
&&
]. The most frequent side effects of AZA include elevated transaminases, leukopenia, recurrent infections, nausea and diarrhoea [52, 55 && ]. The toxic effects, particularly myelosuppression, are augmented in patients with inactive polymorphisms of the enzyme 5-thiopurine-methyltransferase (TPMT), an enzyme that inactivates AZA. In the white population, approximately one in 10 people is heterozygous, and one in 300 is homozygous for the inactive form [56] . An increased risk of lymphoma has been detected in patients treated with AZA for other conditions, such as rheumatoid arthritis and inflammatory bowel disease [57, 58] . In a retrospective series of 99 patients with NMO treated with AZA, three developed lymphoma between 9 and 36 months after AZA initiation [52] . It is not clear, however, whether these patients had been exposed to other immunosuppressants that might have also an increased risk of lymphoma. ]. The optimal interval at which subsequent RTX infusions should occur is not known; while one strategy is to assess the peripheral B-cell population and treat when the B-cell proportion exceeds 0.1% of total lymphocytes, another strategy is to follow the clinical 62] . All patients should be screened for hepatitis B and C before treatment initiation because of an increased risk of viral reactivation or disease progression with RTX [60 & ]. The estimated risk of progressive multifocal leukoencephalopathy is 1 : 25 000 according to data from patients with rheumatoid arthritis treated with RTX [63] ; there have been no case reports of the infection in patients with NMO.
Mitoxantrone is a DNA-intercalating agent and topoisomerase II inhibitor whose use in the treatment of NMO is significantly limited by its toxicities. It has been shown to have absolute ARR reduction by 1.45-2.1 [64, 65] . However, it causes severe dose-related bone marrow toxicity and cardiotoxicity [66] .
Three small studies, each including five patients or fewer, assessed the efficacy of CYC [55 && ,67,68] . One study suggested that CYC is weakly effective (absolute ARR reduction 0.38) but poorly tolerated [55 && ]. The medication causes leukopenia 7-14 days following infusion, gonadal toxicity and is carcinogenic [60 & ]. MTX has not been adequately studied in the treatment of NMO. A retrospective study of 14 patients, 12 of whom received MTX combined with other agents, including prednisolone, RTX and tacrolimus, concluded that its efficacy is comparable with published data on AZA and MMF [69] .
Oral glucocorticoids have been used in many studies as adjunctive agents. Only one study evaluated low-dose periodic glucocorticoid monotherapy for NMO relapse prevention in nine patients [70] . The median ARR declined from 1.48 to 0.49 during the treatment periods. Adverse effects of long-standing oral steroids, however, are numerous and multisystemic [71] .
Combination regimens that have been more consistently used and evaluated include oral glucocorticoids along with AZA or cyclosporine [72] and intravenous methylprednisolone along with mitoxantrone. The benefits of preventive PLEX have also been documented in a small number of patients [73] .
Duration of immunosuppression
Given that the disease course can be unpredictable and that there are no reliable biomarkers for ongoing disease activity, recommendations regarding the optimal duration of preventive treatment have not been established. Some authors propose continuing therapy for 5 years after the last clinical relapse [74] . The decision to limit the duration of therapy is motivated by an attempt to offset risks of long-term toxicity, particularly malignancies that are associated with the use of CYC, AZA and possibly MMF [60 & ]. Any decision regarding the duration of treatment should be individualized and made based upon each patient's clinical course and medication adverse effects.
Special populations and clinical situations
Paediatric neuromyelitis optica Similar to adults, children with NMO require prompt treatment due to severe and rapid onset of disability [75 && ,76] . Therapeutic regimens for children are similar to those used in adults and include intravenous methylprednisolone and PLEX for an acute attack, and long-term immunosuppression for relapse prevention [77 && ].
Women of childbearing age and pregnancy
On average, pregnancy may have a slightly detrimental effect on the relapse rate in NMO; specifically, the frequency of relapses remains relatively unchanged during pregnancy but increases immediately following delivery [78, 79] . In addition, treatment decisions during known or planned pregnancy can be particularly challenging. Most medications used to treat NMO have potentially severe toxicities to the foetus. AZA, MMF and CYC are classified as pregnancy category D; MTX carries pregnancy category label X. None of these medications should be used without concurrent contraception. Although glucocorticoids and RTX are pregnancy category C, it is nevertheless often recommended to discontinue their use in anticipation of pregnancy. It was recently reported that low-dose RTX might be compatible with pregnancy and reduce the occurrence of rebound relapses in the postpartum period, but this observation requires further investigation [80] .
CONTRAINDICATED AGENTS
Several disease-modifying agents used for MS treatment, including interferon-beta (IFN-b) [81] [82] [83] [84] , natalizumab [85] [86] [87] and fingolimod [88] , have a deleterious effect on the relapse rate in NMO patients. This phenomenon reflects the different immunobiology of these two conditions and emphasizes the importance of accurate diagnosis in order to guide optimal treatment decisions. 
EMERGING THERAPIES
CONCLUSION
Optimal management of patients with NMO encompasses effective treatment of acute attacks, reduction of relapses using immunomodulating therapies, symptomatic treatment and rehabilitation, as well as the prevention and management of adverse effects of treatment, comorbidities and secondary conditions. There is a growing evidence base to support the use of various immunosuppressive treatments in the acute and chronic stages of the disease in order to mitigate long-term disability.
There are many open questions regarding the optimal treatment of NMO, however, particularly regarding drug comparisons, duration of treatment and toxicities in children and pregnancy. Future research directed towards identifying biomarkers for seronegative NMO, biomarkers that correlate with disease activity, vaccine strategies and development of highly specific treatment strategies are currently being developed.
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